title: Thrombotic complications without evidence of hemolysis in paroxysmal nocturnal hemoglobinuria: Is eculizumab indicated?
authors: M
authors: M
authors: Bellido
authors: V H J
authors: VH
authors: van der Velden
authors: F W G
authors: FW
authors: Leebeek
authors: P A W
authors: PA
authors: te Boekhorst
mesh_terms: D000328:Adult; D000741:Anemia, Aplastic / Q000209:etiology / Q000628:therapy; D000925:Anticoagulants / Q000009:adverse effects* / Q000627:therapeutic use; D002545:Brain Ischemia / Q000503:physiopathology; D002543:Cerebral Hemorrhage / Q000139:chemically induced* / Q000209:etiology / Q000503:physiopathology; D017809:Fatal Outcome; D006457:Hemoglobinuria, Paroxysmal / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D019693:Hepatitis, Autoimmune / Q000150:complications; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D008641:Mesenteric Vascular Occlusion / Q000150:complications / Q000188:drug therapy*; D017762:Nadroparin / Q000009:adverse effects* / Q000627:therapeutic use; D009778:Occipital Lobe; D010291:Paresis / Q000209:etiology; D010296:Parietal Lobe; D065227:Transfusion Reaction; D020246:Venous Thrombosis / Q000150:complications / Q000188:drug therapy*
chemical_list: D000925:Anticoagulants; D007166:Immunosuppressive Agents; D017762:Nadroparin